Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

selective estrogen receptor covalent antagonist TQB3915

An orally bioavailable, selective and covalent antagonist of estrogen receptor alpha (ERalpha; ERa; ESR1; nuclear receptor subfamily 3, group A, member 1; NR3A1), with potential antineoplastic activity. Upon oral administration, selective estrogen receptor covalent antagonist TQB3915 selectively and covalently binds to and inhibits the activity of ERalpha. This inhibits the growth and survival of ERalpha-expressing cancer cells. ERalpha, a nuclear hormone receptor often overexpressed and/or mutated in a variety of cancer cell types, plays a key role in tumor cell proliferation and survival.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	TQB 3915 TQB-3915 TQB3915

selective estrogen receptor covalent antagonist TQB3915

Search NCI's Drug Dictionary